Wed, Sep 17, 2014, 2:00 AM EDT - U.S. Markets open in 7 hrs 30 mins


% | $
Quotes you view appear here for quick access.

Silver Wheaton Corp. Message Board

rusty_98070 60 posts  |  Last Activity: 14 hours ago Member since: Jul 6, 2002
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • I am so tired of believing in this Company and watching my investment drift down into serious loss territory. I have to admit that in over a dozen years of own GERN stock, I still feel like I care more about the Company than the CEO and his lap dogs---no matter who the present CEO is. I'm beginning to believe they have to agree to a non performance clause when they interview for management positions at GERN.

  • Reply to

    Dr. Huh -- Chairman of the Board

    by end2war 15 hours ago
    rusty_98070 rusty_98070 14 hours ago Flag

    I've seen a lot of guys that are professional bod bodies. They get paid well for their time, it looks good on their resumes and at the Country Club, but they just bring a warm seat to the Board, and nothing else. Looks like Huh fits that bill of being a professional BOD member.

  • I have an AMTD US account and I was able to purchase GGG.V via a broker assisted trade using a placeholder symbol. a few weeks ago That placeholder has been converted to GPHBF. It isn't trading as of Sept. 5th under that OTC symbol, but I expect it to do so very very shortly.

  • Reply to

    Hedge fund manager bites the dust saying...

    by end2war Sep 4, 2014 3:37 PM
    rusty_98070 rusty_98070 Sep 4, 2014 4:31 PM Flag

    All those pricks have to do is throw a .10 tax per transaction, and that would end it. But that would get in the way of the revolving door hiring of lackeys once they retire from their lazy azzed jobs at the SEC

  • Novartis reception vs. Geron's a brief quote:
    A new study reports one of the biggest potential advances against heart failure in more than a decade — a first-of-a-kind, experimental drug that lowered the chances of death or hospitalization by about 20 percent.

    Doctors say the Novartis drug — which doesn't have a name yet — seems like one of those rare, breakthrough therapies that could quickly change care for more than half of the 6 million Americans and 24 million people worldwide with heart failure.

    "This is a new day" for patients, said Dr. Clyde Yancy, cardiology chief at Northwestern University in Chicago and a former American Heart Association president.

    "It's been at least a decade since we've had a breakthrough of this magnitude," said Yancy, who had no role in the study.

    It involved nearly 8,500 people in 47 countries and was the largest experiment ever done in heart failure. It was paid for, designed and partly run by Novartis, based in Basel, Switzerland. Independent monitors stopped the study in April, seven months earlier than planned, when it was clear the drug was better than an older one that is standard now.

    During the 27-month study, the Novartis drug cut the chances of dying of heart-related causes by 20 percent and for any reason by 16 percent, compared to the older drug. It also reduced the risk of being hospitalized for heart failure by 21 percent.

    "We are really excited," said one study leader, Dr. Milton Packer of UT Southwestern Medical Center in Dallas. The benefit "exceeded our original expectations."

  • The pros may be beating GERN into the deck, but if you look at INCY Jan 2016 Puts, they are very expensive, indicating that the players don't have a lot of hope of INCY NOT crashing.

  • rusty_98070 rusty_98070 Aug 27, 2014 11:38 AM Flag

    FABULOUS results!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! Thanks

  • Reply to

    Large blocks

    by daytrader19 Aug 26, 2014 10:25 AM
    rusty_98070 rusty_98070 Aug 26, 2014 10:31 AM Flag

    Plus the new level of short manipulative posts on this board is fascinating. Almost all the posters here have been placed on ignore, as their goal is to obfuscate any relevant posts and discourage investors.

  • Reply to

    Large blocks

    by daytrader19 Aug 26, 2014 10:25 AM
    rusty_98070 rusty_98070 Aug 26, 2014 10:29 AM Flag

    Yes, I noticed, most of them buys, but the algos and working hard at slamming the price down. The march of the algos is tough. The vol. with no news is unusual.

  • Reply to

    Suppressing tumor growth via telomerase

    by hayflicklim Aug 17, 2014 3:03 PM
    rusty_98070 rusty_98070 Aug 17, 2014 4:15 PM Flag

    how about a ref to the article.

  • "...... but these days biotech shorts are the most dangerous of all because there is so much imagination involved and so few data points. "

  • Geron will react to the CC in after hours trading. If it is the news we all expect, there will be panic buying by shorts to cover, and there will be limited sellers. This should spike the price. Since GERN has elected to present this blockbuster news during the after hours period, I believe they are fully aware of what will happen to the SP, and probably have a couple of magnums of champagne on ice as they watch the short panic.

  • Reply to

    Is the Call At 1:30 ET///???

    by kipk20122 Aug 11, 2014 11:01 AM
    rusty_98070 rusty_98070 Aug 11, 2014 11:03 AM Flag

    From Gern's site:
    Q2 2014 Geron Earnings Conference Call
    Monday, August 11, 2014 1:30 p.m. PT

  • rusty_98070 rusty_98070 Aug 10, 2014 8:30 PM Flag

    Gee, thanks for pointing out the breaking news.

  • rusty_98070 rusty_98070 Aug 9, 2014 5:33 PM Flag

    New Drug Induces Remissions in Myelofibrosis
    The results of a Mayo Clinic study demonstrate that
    a drug named imetelstat induces remissions in some
    patients with myelofibrosis. This is a form of chronic
    leukemia that affects the patient’s bone marrow
    that is replaced by fibrosis (scar tissue) instead
    of blood-producing cells.
    Scientists do not yet know the exact mechanism of
    acttion for imetelstat, but believe it interferes with the
    survival and proliferation of cancer cells by inhibiting
    a critical enzyme called telomerase. One of the functions
    of telomerase is to repair the ends of chromosomes
    called telomeres, and because cancer cells have shorter
    than normal telomere size, they are particularly susceptible
    to the drug.
    The study results are promising. Some patients
    participating in the clinical trial taking imetelstat obtained
    dramatic responses, and we have seen some complete
    responses (tantamount to a cure), which is almost
    unheard of in this disease.
    Research is the fundamental reason that people across
    the globe are living longer, healthier lives.
    Mayo Clinic applies basic science to unlock the
    destructive secrets of cells and discover how to repair
    or reverse the damage. We then translate that knowledge
    into first-time cures and treatments for a wide range
    of life-threatening diseases and chronic conditions.
    Patients receive research-driven care at Mayo Clinic,
    which possesses a long legacy of providing a
    team-based approach to integrating patient care,
    research, and education.
    Although patients may experience relief in response
    to other treatments, their bone marrow does not
    usually return to normal. But in the case of this new
    therapy, some of the patients participating in the trial
    developed normal bone marrow.
    Researchers studied imetelstat in 33 patients at
    Mayo Clinic and have now followed the first 22 patient

  • Reply to

    Simple Reason for IND/IST Transfer

    by irishtrader52 Aug 7, 2014 9:37 AM
    rusty_98070 rusty_98070 Aug 7, 2014 2:08 PM Flag

    Thanks Taz,
    Just took a quick run through on the discussions you brought to our attention. Smart people saying complicated things. Easy enough for the uneducated to skim and get a sense of the promise held out, though.

  • Reply to

    "Imetelstat Strong" and the New Organization

    by sidesaddlex Aug 7, 2014 8:08 AM
    rusty_98070 rusty_98070 Aug 7, 2014 10:51 AM Flag

    Just wanted to add (for others' benefit ) after reading this post of yours, I went back and read all the posts you've contributed over the last 3 months. I have to say you have a ring of credibility though out all your posts,
    when viewed through a retrospective lens that lends credence to this post. So, I'm a fan and looking forward to the 11th.

  • One can surmise until the cows come home, but a quick scan of the last hours trading clearly indicate a determined effort to keep the share price down. Whether it is generic shorts or competing drug cos. the nefarious plan is obvious when you look at the minute chart.

  • Nice to see some buying with conviction.

  • Reply to

    What is going on REALLY!!!!

    by golflogo Aug 5, 2014 3:45 PM
    rusty_98070 rusty_98070 Aug 6, 2014 10:44 AM Flag

    Gern is one heck of a buy. Probably see a 50% bump on the 11th CC. Then it is just a question whether to hold or take the quick profit. Holding for two years will probably make you a lot of money. One aspect to investing at this point in time in a bio tech like GERN is that it is largely independent of the overall market--once it starts to move. And, if you believe we are on the edge of the mother of all pullbacks, then it is another reason to buy.

23.06+0.23(+1.01%)Sep 16 4:02 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.